Characteristics of Ankylosing Spondylitis Associated Uveitis

NCT07113834 | Completed

• 1 other identifier: Ankylosing
• Study Type: observational
• Target: 22
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to understand the clinical characteristics associated with AAU in Egyptian AS patients, and the prognostic factors, in terms of the Corrected Distance Visual Acuity (CDVA).

Conditions

Uveitis

Keywords

Ankylosing Spondylitis; Uveitis

Outcome Measures

Primary Outcomes (1)

• Change in Corrected Distance Visual Acuity (CDVA)

  CDVA was assessed at baseline (initial presentation) and after treatment (follow-up average of 3 months), using the Logarithm of the Minimum Angle of Resolution (logMAR) scale. Improvement or deterioration in CDVA was evaluated in relation to clinical characteristics, treatment modalities, and complication development.

  Baseline and 3-month follow-up

Interventions

Adalimumab DRUG

A tumor necrosis factor-alpha (TNF-α) inhibitor used as a biologic agent for the treatment of ankylosing spondylitis. Administered subcutaneously as part of systemic immunomodulatory therapy.

Systemic corticosteroids DRUG

Oral or intravenous corticosteroids (e.g., prednisolone) used to suppress systemic inflammation in cases of active AS or severe uveitis.

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

This study included a retrospective cohort of 22 Egyptian patients (26 eyes) diagnosed with Ankylosing Spondylitis-associated Acute Anterior Uveitis (ASAAU), who were referred to the Ophthalmology Clinics of Benha University - Faculty of Medicine from the Spine Clinic at the same institution between September 2023 and August 2024. The cohort was composed of adult patients who met the Modified New York Criteria for AS and had documented ophthalmic symptoms confirmed as AAU through clinical and imaging evaluation. All included patients had complete follow-up data and received appropriate treatment for both AS and uveitis.

You may qualify if:

• Egyptian nationality.
• Age: ≥ 18 years.
• Confirmed diagnosis of Ankylosing Spondylitis (AS) according to the Modified New York Criteria, including:
• Clinical symptoms (e.g., chronic inflammatory back pain, reduced lumbar motion, reduced chest expansion)
• Radiographic evidence of sacroiliitis.
• Confirmed diagnosis of Acute Anterior Uveitis (AAU) based on:
• Ophthalmologic examination (e.g., slit-lamp biomicroscopy)
• Ancillary testing (e.g., Optical Coherence Tomography \[OCT\] and/or Fluorescein Angiography \[FA\]).
• Presentation to the Spine Clinic of Benha University - Faculty of Medicine between September 2023 and August 2024 with ophthalmic complaints, subsequently referred to the Ophthalmology Clinic.
• Complete medical and ophthalmologic records available.
• Received treatment for both AS and AAU.
• At least one follow-up visit after initiation of treatment.

You may not qualify if:

• Non-Egyptian patients.
• History of other systemic autoimmune or immunological diseases (e.g., sarcoidosis, Behçet's disease, systemic lupus erythematosus).
• Uveitis due to non-autoimmune secondary causes (e.g., infectious uveitis, trauma-related uveitis).
• History of ocular surgery prior to the episode of AAU

Sponsors & Collaborators

• Benha University: lead

Study Sites (1)

Benha University

Banhā, Cairo Governorate, 13111, Egypt

Location

MeSH Terms

Conditions

Uveitis; Spondylitis, Ankylosing

Interventions

Adalimumab

Condition Hierarchy (Ancestors)

Uveal Diseases; Eye Diseases; Axial Spondyloarthritis; Spondylarthropathies; Spondylarthritis; Spondylitis; Spinal Diseases; Bone Diseases; Musculoskeletal Diseases; Ankylosis; Joint Diseases; Arthritis

Intervention Hierarchy (Ancestors)

Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Lecturer

Study Record Dates

• First Submitted: August 3, 2025
• First Posted: August 11, 2025
• Study Start: September 1, 2023
• Primary Completion: September 1, 2023
• Study Completion: August 1, 2024
• Last Updated: August 11, 2025

Record last verified: 2023-09

Locations

EG (1)